Vera Therapeutics (VERA) Short term Debt (2021 - 2023)

Vera Therapeutics has reported Short term Debt for 3 years, with the latest figure at $3.1 million in Q1 2023.

• For the quarter ending Q1 2023, Short term Debt rose 87.2% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2023 stood at $3.1 million (up 87.2% YoY), and the FY2022 full-year result was $2.8 million, up 172.02% from the prior year.
• Short term Debt for Q1 2023 stood at $3.1 million, up from $2.8 million in the prior quarter.
• The five-year high for Short term Debt was $3.1 million in Q1 2023, with the low at $994000.0 in Q3 2021.
• Historically, Short term Debt has averaged $1.7 million across 3 years, with a median of $1.6 million in 2022.
• The largest YoY upside for Short term Debt was 172.02% in 2022 against a maximum downside of 1.01% in 2022.
• Vera Therapeutics' Short term Debt stood at $1.0 million in 2021, then surged by 172.02% to $2.8 million in 2022, then rose by 10.43% to $3.1 million in 2023.
• The last three Short term Debt figures came in at $3.1 million (Q1 2023), $2.8 million (Q4 2022), and $1.0 million (Q3 2022), per Business Quant data.